

1 An in-depth investigation of the safety and immunogenicity of an inactivated
2 SARS-CoV-2 vaccine

3 Jing Pu^{#,1}, Qin Yu^{#,2}, Zhifang Yin^{#,3}, Ying Zhang^{#,1}, Xueqi Li^{#,1}, Dandan Li^{#,1}, Hongbo Chen^{#,1}, Runxiang Long¹,
4 Zhimei Zhao¹, Tangwei Mou¹, Heng Zhao¹, Shiyin Feng², Zhongping Xie¹, Lichun Wang¹, Zhanlong He¹, Yun
5 Liao¹, Shengtao Fan¹, Qiongzhou Yin¹, Ruiju Jiang¹, Jianfeng Wang³, Lingli Zhang², Jing Li¹, Huiwen Zheng¹,
6 Pingfang Cui¹, Guorun Jiang¹, Lei Guo¹, Mingjue Xu¹, Huijuan Yang¹, Shan Lu⁴, Xuanyi Wang⁵, Yang Gao¹,
7 Xingli Xu¹, Linrui Cai², Jian Zhou¹, Li Yu¹, Zhuo Chen², Chao Hong¹, Dan Du², Hongling Zhao¹, Yan Li¹, Kaili
8 Ma¹, Yunfei Ma¹, Donglan Liu¹, Shibao Yao¹, Changgui Li^{*,3}, Yanchun Che^{*,1}, Longding Liu^{*,1}, Qihan Li^{*,1}

9
10 1, Institute of Medical Biology, Chinese Academy of Medicine Science & Peking Union Medical College,
11 Yunnan Key Laboratory of Vaccine Research and Development for Severe Infectious Diseases, Kunming,
12 650118, China

13 2, National Drug Clinical Trial Institution of West China Second Hospital, Sichuan University, Chengdu,
14 610041, China

15 3, National Institute of Food and Drug Control, Beijing, 100050, China

16 4, Department of Medicine, University of Massachusetts Medical School, Worcester, MA 01655, USA

17 5, The Institutes of Biomedical Science, Shanghai Medical College, Fudan University, Shanghai, 200032,
18 China

19

20 **# Co-first authors:**

21 Jing Pu, Qin Yu, Zhifang Yin, Ying Zhang, Xueqi Li, Dandan Li and Hongbo Chen contributed
22 equally to this study.

23

24 *** Corresponding author:**

25 Qihan Li, MD, PhD

26 Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical

27 College.

28 935 Jiaoling Road, Kunming, Yunnan, China, 650118.

29 Tel: 86-871-68335905.

30 Fax: 86-871-68334483.

31 E-mail: liqihan@imbcams.com.cn

32

33 Longding Liu, PhD

34 Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical

35 College.

36 E-mail: liuld@imbcams.com.cn

37

38 Yanchun Che, MS

39 Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical

40 College.

41 E-mail: cheyanchun@imbcams.com.cn

42

43 Changgui Li, PhD

44 National Institute of Food and Drug Control, China

45 E-mail: changguili@aliyun.com

46

47

48 **Abstract**

49 BACKGROUND

50 In-depth investigations of the safety and immunogenicity of inactivated SARS-CoV-2 vaccines
51 are needed.

52 METHOD

53 In a phase I randomized, double-blinded, and placebo-controlled trial involving 192 healthy
54 adults 18-59 years of age, two injections of three different doses (50 EU, 100 EU and 150 EU)
55 of an inactivated SARS-CoV-2 vaccine or the placebo were administered intramuscularly with
56 a 2- or 4-week interval between the injections. The safety and immunogenicity of the vaccine
57 were evaluated within 28 days.

58 FINDING

59 In this study, 191 subjects assigned to three doses groups or the placebo group completed
60 the 28-day trial. There were 44 adverse reactions within the 28 days, most commonly mild
61 pain and redness at the injection site or slight fatigue, and no abnormal variations were
62 observed in 48 cytokines in the serum samples of immunized subjects. The serum samples
63 diluted from 1:32 to 1:4096 and incubated with the virus did not show antibody-dependent
64 enhancement effects (ADEs) with regard to human natural killer cells, macrophages or
65 dendritic cells. At day 14, the seroconversion rates had reached 92%, 100% and 96% with
66 geometric mean titers (GMTs) of 18.0, 54.5 and 37.1, and at day 28, the seroconversion rates
67 had reached 80%, 96% and 92% with GMTs of 10.6, 15.4 and 19.6 in 0, 14 and 0, 28
68 procedures, respectively. Seroconversion was associated with the synchronous upregulation
69 of ELISA antibodies against the S protein, N protein and virion and a cytotoxic T lymphocyte
70 (CTL) response. Transcriptome analysis shaped the genetic diversity of immune response
71 induced by the vaccine.

72 INTERPRETATION

73 In a population aged 18-59 years, this inactivated SARS-CoV-2 vaccine was safe and
74 immunogenic.

75 Trial registration: NCT04412538

76 FUNDING: The National Key R&D Program of China (2020YFC0849700), the Program of
77 Chinese Academy of Medicine Science and the Major Science and Technology Special
78 Projects of Yunnan Province.

79

80 Coronavirus disease 2019 (COVID-19) is caused by a novel member of the Coronaviridae
81 family called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). From the
82 emergence of COVID-19 at the end of 2019 to September 2020, more than 26 million cases
83 and more than 800,000 deaths had been recorded, indicating that COVID-19 poses a
84 substantial threat to public health worldwide ¹. Because of the highly contagious nature of
85 SARS-CoV-2 and the severe clinical outcomes ^{2,3}, one of the primary strategies to control the
86 pandemic is to develop an effective vaccine, and within a short period, clinical trials of
87 several vaccines have been initiated ⁴⁻⁷. To date, the data obtained from phase I/II clinical
88 trials have focused on serological detection to assess the immunogenicity of these vaccines
89 ^{4,7,8}. The data suggest that SARS-CoV-2, an enveloped virus, possesses various encoded
90 antigenic components, including S (spike), N (nucleocapsid), E (envelope) and M (membrane)
91 antigens ⁹, all of which might theoretically be recognized by the immune system during
92 infection; however, the key antigen is the S protein, which mediates virion entry into cells by
93 interacting with the ACE2 receptor ¹⁰. Our previous work, based on an analysis of the
94 composition of antibodies in convalescent serum from COVID-19 patients, suggested a
95 technical strategy for the preparation of an inactivated SARS-CoV-2 vaccine in which the
96 inactivation process yields an inactivated virion exposing the S, N and other viral antigens.
97 This vaccine was found to effectively elicit immune protection in nonhuman primates under
98 viral challenge and was approved for a phase I clinical trial (permission number: 2020L00020
99 by the Chinese Food and Drug Administration (CFDA); clinical trial registration number:
100 NCT04412538). Here, we further investigated the safety and immunogenicity of this vaccine
101 in immunized individuals in a phase I trial, especially focusing on safety with regard to the
102 immunopathology of the vaccine. The results obtained are encouraging, and further study is
103 needed.

104

105 **Materials and Methods**

106 ***Viruses and cells***

107 All SARS-CoV-2 virus strains used in this work were isolated from hospitalized patients
108 including indigenous and imported cases confirmed COVID-19 in Yunnan Hospital of
109 Infectious Diseases from January to May 2020. The strain with mutation of D614G in S
110 protein was isolated from a child patient who returned from U.S. to hometown and was
111 identified being infected by SARS-CoV-2 through clinical diagnostic and q-RT-PCR in March,
112 2020. The virus was proliferated in Vero cells (WHO) and was titrated with a microtitration
113 assay. Vero cells were cultured in Dulbecco's modified Eagle's medium (DMEM; Corning, NY,
114 USA) containing 5% fetal bovine serum (FCS; HyClone, Logan, USA).

115

116 ***Inactivated vaccine***

117 The SARS-CoV-2 inactivated vaccine was developed by the Institute of Medical Biology (IMB),
118 Chinese Academy of Medical Sciences (CAMS). Briefly, the virus strain, named KMS-1
119 (GenBank No: MT226610.1), was inoculated into Vero cells for production in an environment
120 that met the BSL requirements. The harvested viruses were inactivated by formaldehyde
121 (v:v=1:4000) for 48 h to lyse the viral membrane, purified via chromatography and
122 concentrated. A second inactivation with beta-propiolactone (v:v=1:2000) was performed to
123 destroy the viral genomic structure, followed by a second purification and concentration
124 using the same protocol. The vaccine stock was evaluated using various quality indexes,
125 including antigen content, immunogenicity, sterility and residue testing. The viral antigen
126 content was measured via ELISA. The vaccine contained 50, 100 or 150 EU of inactivated viral
127 antigen adsorbed to 0.25 mg of Al(OH)₃ adjuvant and suspended in 0.5 ml of buffered saline
128 for each dose. The placebo contained only the same amount of Al(OH)₃ in buffer.

129

130 ***Study design and participants***

131 The trial was designed based upon the principles of randomization, double-blinding and
132 placebo control. The study protocol was reviewed and approved by the Ethics Committee of
133 the West China Second University Hospital, Sichuan University. An independent data safety
134 monitoring board was established to oversee the safety data during the study, specifically
135 during the 7 days after each inoculation (p.i.). The trial was conducted according to the
136 principles of the Declaration of Helsinki and Good Clinical Practice at the West China Second
137 University Hospital, Sichuan University. Healthy volunteers 18 to 59 years of age were eligible
138 for enrollment after providing informed consent. The inclusion and exclusion criteria are
139 listed in the supplementary appendix. The enrolled participants were randomly assigned at a
140 ratio of 1:1 to receive two inoculations at an interval of 14 days or 28 days, and the subjects
141 in each schedule were assigned at a ratio of 1:1:1:1 to receive one of the three vaccine doses
142 (50 EU, 100 EU and 150 EU) or the placebo. All the enrolled participants were asked to record
143 solicited and unsolicited adverse events, if any, for a period of 28 days. Study staff visited
144 participants on site to track their health status and determine whether they needed medical
145 care. Blood samples were taken from the enrolled participants at days 0 (baseline), 7, 14 and
146 28 (0, 14 schedule) or 7 and 28 (0, 28 schedule) days postimmunization to evaluate the
147 immunogenicity of the vaccine at different time points and to determine the vaccine safety
148 profile through the detection of 48 cytokines in the serum, the assessment of possible ADEs
149 with regard to viral infection and the analysis of mRNA gene expression in peripheral blood
150 mononuclear cells (PBMCs).

151

152 ***End points of the clinical trial***

153 The primary end point was the total rate of adverse reactions from 0 to 28 days
154 postimmunization. The secondary end points were serological evidence of the

155 immunogenicity of the vaccine.

156

157 ***Statistical analysis***

158 Descriptive statistics (means and standard deviations for normally distributed variables,
159 medians and IQRs for nonnormally distributed variable) were used for continuous variables,
160 while frequencies and proportions were used for categorical variables. The safety analysis
161 was performed with the data from the participants who had received at least one dose of
162 the vaccine and for whom safety data were available. The numbers and proportions of
163 participants with adverse reactions or events were summarized. The immunogenicity
164 analysis was conducted with the data from the full cohort, including all participants who
165 received injections and had results for the antibody test. The antibodies against SARS-CoV-2
166 are summarized as geometric mean titers with 95% CIs, and the cellular responses are
167 presented as the proportion of positive responders. The chi-square test or Fisher's exact test
168 was used to analyze the categorical data, and the t-test or Wilcoxon rank-sum test (for
169 nonnormally distributed data) was used to compare log-transformed antibody titers. A P
170 value lower than 0.05 (two-sided) was considered to be significant. The statistical analysis
171 was performed by an independent statistician using GraphPad Prism software (San Diego, CA,
172 USA) and STATA software (Version 15.0; STATA Corp., College Station, TX, USA).

173

174 ***Laboratory detection***

175 ***Neutralizing antibody test***

176 The neutralizing antibody assay was performed via microtitration, and the neutralizing titer
177 in the sera was determined by CPE observation. A brief description is attached in the
178 supplemental appendix.

179 ***ELISA***

180 ELISAs were conducted with antibodies against the S protein, N protein and virions that were
181 developed by this institute. A brief description can be found in the supplemental appendix.

182 ***ELISpot***

183 An ELISpot assay was performed with a Human IFN- γ ELISpot Kit (Mabtech, Cincinnati, OH,
184 USA) according to the manufacturer's protocol. A brief description is attached in the
185 supplemental appendix.

186 ***Immune cell populations***

187 The isolation of immune cell populations was performed according to a standard protocol. A
188 brief description can be found in the supplemental appendix.

189 ***Cytokine assay***

190 Detection of 48 cytokines in human peripheral blood was performed according to the kit
191 manufacturer's instructions. A brief description is attached in the supplemental appendix.

192 ***Transcriptome assay***

193 Transcriptome assays were performed by Novogene Co., Ltd., China. To exclude individual
194 differences, each group included two samples (A and B) at each time point, and each sample
195 was mixed with PBMCs from five individuals. The raw microarray data were submitted to the
196 National Genomics Data Center (NGDC) and are available (PRJCA003531). A brief description
197 is attached in the supplemental appendix.

198

199 ***ADE detection***

200 Human NK cells, DCs, and mononuclear/macrophages isolated from donors who provided
201 their informed consent were infected by the virus in different multiplicities of infection (MOIs)
202 in the presence of mixed sera from 12 immunized individuals that had the same neutralizing
203 titer and were diluted from 1:32 to 1:4096. Antibody-dependent enhancement (ADE) was
204 determined via viral load detection by q-RT-PCR at various time points. A brief description is

205 attached in the supplemental appendix.

206 **qRT-PCR**

207 The RNA extraction and qRT-PCR assay was according standard protocol. The brief
208 description can be seen in supplemental appendix.

209

210 **Results**

211 **Study participants**

212 A total of 294 adults aged 18 to 59 years were evaluated for inclusion in this phase I trial.
213 Among them, 102 persons were excluded, of whom 84 were ineligible, and 18 withdrew
214 their informed consent. The remaining 192 participants were randomly assigned at a ratio of
215 1:1 to receive two inoculations with an intervening interval of 14 days or 28 days, and
216 subjects for each schedule were assigned at a ratio of 1:1:1:1 to receive one of the three
217 doses of the vaccine or the placebo (Fig. 1).

218 From May 2020 through August 2020, all participants who received two inoculations of
219 the vaccine or placebo were monitored for any clinical manifestations and were required to
220 provide blood samples 3 (0, 14 schedule) or 2 (0, 28 schedule) times after inoculation. The
221 withdrawal rate was 0.5%: 1 participant in the low-dose group who was assigned to the 0, 28
222 schedule did not receive the second dose. The 191 participants were divided as follows: 24 in
223 each of the three different dose groups and the control group assigned to the 0, 14 schedule
224 and 23, 24, 24 and 24 in the low-dose, medium-dose, high-dose and control groups assigned
225 to the 0, 28 schedule (Fig. 1). The demographic characteristics of the participants in each
226 group are shown in Table 1.

227

228 **Comprehensive observation of adverse reactions**

229 Because knowledge of the pathogenesis of SARS-CoV-2 infection is still lacking^{11,12}, in this

230 trial, the specific vaccine safety concern was abnormal immunopathologic events. We
231 observed not only solicited clinical adverse reactions for 7 days after each inoculation and
232 unsolicited events for 28 days after the full vaccination but also the variations in cytokine
233 levels in the serum of 50% of the subjects inoculated with the vaccine or placebo.
234 Furthermore, based on the serious concern regarding a possible ADE effect in vaccine
235 development ¹³, the immune serum samples from vaccinated individuals were investigated
236 across a range of dilutions for possible ADE. The 18 solicited systemic adverse reactions
237 observed in the 7 days after each inoculation were distributed as follows: 3, 1, 1 and 0 in the
238 low-dose, medium-dose, high-dose and placebo groups assigned to the 0 and 14 schedule
239 and 2, 4, 4, and 3 in those groups assigned to the 0 28 schedule. Unsolicited reactions were
240 reported by 8.3%, 0.0%, and 8.3% of the participants in the low-, medium- and high-dose
241 groups compared to 0.0% in the placebo group among those assigned to the 0, 14 schedule,
242 while they were reported by 0.0%, 8.3%, and 12.5% of the participants in the low-, medium-
243 and high-dose groups compared to 4.2% in the placebo group among those assigned to the 0,
244 28 schedule. The most common adverse reactions were mild pain and redness at the
245 injection site and slight fatigue. No severe (grade 3) adverse reactions or serious reactions
246 were observed within 28 days (Table 2). Furthermore, the levels of various cytokines in the
247 sera of immunized subjects in the 3 dose groups following the 2 schedules did not show
248 abnormalities compared to those in the sera from subjects in the placebo groups (Fig. 2).
249 There were no significant differences between the vaccine and placebo groups with regard to
250 the counts of various T cell populations in the peripheral blood (Supplemental Fig. 1). To
251 investigate possible ADE in individuals immunized with the inactivated vaccine, immune sera
252 collected from 15 subjects with similar neutralizing antibody titers were mixed and diluted
253 from 1:32 to 1:4096 and then incubated with SARS-CoV-2 for inoculating the cultured human
254 DCs, NK cells and mononuclear cells/macrophages followed by the detection of dynamic viral

255 proliferation in the cells and supernatant. The results did not show variations of dynamic
256 viral proliferation with existence of immune sera rather than 1-2 fold compared to viral
257 control, and suggest that the immunized sera in the dilution range of 1:32 to 1:4096 do not
258 lead to ADE in these human immune cells compared with sera from individuals in the
259 placebo group and the positive Dengue virus control group (Fig. 3). These results suggest that
260 there are no immunopathologic events related to vaccination.

261

262 **Assessment of immunity elicited in the 3 dose groups assigned to the 2 schedules**

263 The results obtained for the three dose groups assigned to the two schedules with regard
264 to the neutralizing antibody titers of the immunized subjects in the groups assigned to the 0,
265 14 schedule showed seroconversion rates of 55%, 100% and 88% in the low-, medium- and
266 high-dose groups compared to the placebo group at day 7 after the booster, and their
267 geometric mean titers (GMTs) increased by 5.0, 42.5 and 24.4, respectively. Furthermore, at
268 day 14, the seroconversion rates in the three groups reached 92%, 100% and 96%, with GMTs
269 of 18.0, 54.5 and 37.1, respectively (Fig. 4a). However, there appeared to be a decreasing
270 trend in the neutralizing antibody titers from day 14 to day 28 (Fig. 4a). In the groups
271 assigned to the 0, 28 schedule, the seroconversion rate of the neutralizing antibodies
272 reached 80%, 96% and 92%, with GMTs of 10.6, 15.4 and 19.6, at day 28 after immunization,
273 with an increasing trend starting from day 7 after immunization (Fig. 4b). Significantly, ELISA
274 with antibodies against the S protein, N protein and virion showed essentially synchronous
275 increases regardless of the schedule to which the participants were assigned (Fig. 4a, b). The
276 specific positive CTL responses against the S protein, N protein and virion in the ELISpot assay
277 indicated a distinct increase at day 28 after the booster for both schedules (Fig. 4a, b). These
278 results suggest that the vaccine elicits a synchronous dynamic response involving antibodies
279 and CTLs against the viral antigens. The subsequent serological detection in the available

280 serum samples of 23 subjects immunized with the medium dose of the vaccine at 90 days
281 after the second inoculation suggested that the seroconversion rate of the neutralizing
282 antibodies was 91.3% with a GMT of 8.5, while the ELISA antibodies showed 100% of
283 seroconversion including anti-S, anti-N and anti-virion antibodies of 91%, 61% and 83% with
284 GMTs of 656, 594 and 691, respectively (Fig. 4c). The IgG1 subtype was the common subtype
285 against all three antigens (Table S1). Additionally, the immune sera were found to neutralize
286 the pandemic strains in North America (Fig. 4d) with the D614G mutation in the S protein
287 (Supplemental Fig. 2)¹⁴. To characterize the immunogenicity of the vaccine, we performed a
288 comparative analysis of the mRNA profile of PBMCs from immunized individuals of
289 medium-dose group in two schedules at day 7 and 28 after full immunization to shape the
290 genetic diversity of the immune response elicited by the vaccine. The results suggest that the
291 vaccine initiates and promotes a series of transcriptional activities in immune cells, which
292 lead to the significant upregulation of many genes related to the immune response. The
293 classification of all the different upregulated genes into various immune functions suggests
294 that the immunization by the vaccine of medium-dose in two schedules results in the specific
295 activation of the innate and adaptive immune responses compared to the placebo control.
296 However, the expression of certain significant cytokine genes, including IL-6, IL-1, IL-2, TNF- α
297 and IFN- γ , which were found to be distinctly increased in the peripheral blood of COVID-19
298 patients, varied only slightly compared to those in the placebo controls (Fig. 5a).
299 Furthermore, our data indicate that the genes related to T and B cell activation were
300 upregulated by approximately 40% and 25%, respectively, at day 7 after the second
301 inoculation and varied dynamically during the periods from day 7 to day 14 or from day 7 to
302 day 28 in two schedules (Fig. 5b, c). The genes related to the activation of DCs, mononuclear
303 cells/macrophages and NK cells were upregulated to varying degrees in the same periods (Fig.
304 5d, e, f). All these results describe a specific genetic background of the immune response

305 elicited by the vaccine.

306

307 **Discussion**

308 Given the urgent need to control the COVID-19 pandemic, vaccine development is being
309 accelerated into the clinical trials phase^{4,7,8}, even though understanding of the immunologic
310 features of the antigens of SARS-CoV-2 remains poor. In this phase I trial, a study was
311 performed to investigate the safety and immunogenicity of this inactivated vaccine in 191
312 subjects. The data collected show several notable features. First, the clinical safety
313 observations among the 191 subjects suggest that there were no severe adverse reactions
314 related to vaccination, and the most frequently reported events were mild, including redness,
315 itching and swelling at the inoculation site and a few cases of slight fatigue; there were no
316 significant differences between the vaccine and control groups. These data support the
317 clinical safety of this vaccine. However, based on the current concern about the possibility of
318 immunopathology due to SARS-Cov-2 infection¹³, we extended our safety observation to the
319 investigation of variations in cytokine levels in the serum, with particular attention paid to
320 the possibility of ADE related to antibodies induced by vaccination^{12,15}. The test results
321 suggested that there were no abnormalities in most of the 48 detected cytokines. In the
322 dilution range of 1:32 to 1:4096, no ADE was observed in the virus-infected DCs, NK cells or
323 mononuclear cells/macrophages in the immune sera from vaccinated individuals. Although
324 we cannot conclude that this vaccine will not cause ADE, these observations at least suggest
325 that the likelihood of ADE as a result of inoculation with this vaccine is small. Second,
326 serological detection showed not only neutralizing antibody but also ELISA antibodies against
327 the S protein, N protein and complete virion antigens elicited in the vaccinated population,
328 and there were dynamic alterations based on the dose and vaccination schedule. However,
329 the medium and high doses in both the 0, 14 and 0, 28 schedule groups led to 100%

330 seroconversion of ELISA anti-S antibody after two inoculations, and interestingly, the medium
331 dose group assigned to the 0, 14 schedule reached 100% seroconversion of the neutralizing
332 antibody with the highest GMT value. Importantly, the neutralizing antibody can neutralize
333 different pandemic strains with diverse mutations. At the time of the antibody response, a
334 CTL response with IFN- γ specificity against the S, N and virion antigens was detected in
335 immunized individuals in comparison with individuals receiving placebo, which suggests that
336 any one of three antigens enables the specific activation of T cells, even if they do not show
337 dose-dependent effects. These immunological indexes indicate a systemic immune response
338 elicited by our vaccine in the human population. To shape the genetic diversity of the specific
339 immunity elicited by the vaccine, we examined the mRNA gene profile of the PBMCs from
340 vaccinated individuals and found that most of the expressed mRNA genes were related to
341 various signaling pathways of the innate and adaptive immune systems, and the immune
342 functions were upregulated in comparison with the placebo group. Here, activation of the
343 multiple signaling pathways involved in the immune response resulted in variations in
344 hundreds of genes related to activation of innate immunity at day 7 after immunization
345 regardless of the immunization schedule; however, the cytokines that were found to have
346 elevated levels in COVID-19 patients had only mild variations and were at levels similar to
347 those in the placebo control group, which corresponded with those detected in the serum.
348 The activation of genes related to T cells, B cells, DCs and mononuclear cells/macrophages
349 with varying dynamics is evidence of the immune response elicited by the vaccine. All the
350 data obtained in this trial support the safety and immunogenicity of this inactivated vaccine
351 and are encouraging with regard to further studies of its efficacy in the future.

352 A limitation of this study is the lack of protective efficacy analysis and data from a parallel
353 contrasting analysis of the transcriptome of PBMCs from individuals immunized with the
354 vaccine and of those from COVID-19 patients, which was due to a lack of samples.

355

356 **Acknowledgments**

357 We appreciate the contributions of all investigators at West China Second Hospital of Sichuan
358 University who worked on the trial. This work was supported by the National Key R&D
359 Program of China (2020YFC0849700), the Program of Chinese Academy of Medicine Science
360 and the Major Science and Technology Special Projects of Yunnan Province.

361

362 **Conflicts of interest**

363 The sponsor of the study played no role in the study design, data and sample collection, data
364 processing, or report writing. The corresponding author had full access to all the data
365 generated by the study and takes full responsibility for the final submission for publication.

366

367 **Author contributions**

368 Conceived of and designed the experiments: QL, CL, YC, and LL. Performed the experiments:
369 JP, QY, ZY, YZ, XL, DLi, ZZ, RL, HC, TM, HZ, SF, ZX, LW, ZH, YL, SF, JW, LZ, JL, HZheng, PC, GJ, LG,
370 MX, HY, YG, XX, LC, LY, ZC, and DD. Analyzed the data: QL, CL, YC, LL, JP, YZ, DLi and ZZ.
371 Contributed reagents/materials/analysis tools: QY, JR, JZ, CH, HZhao, YL, KM, DLiu, SL, XW
372 and SY. Wrote the paper: QL, YC, YZ, DLi and ZZ. The manuscript was drafted by QL.

373

374 **Reference**

- 375 1. Johns_Hopkins_University. COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at
376 Johns Hopkins University (JHU), 2020.
- 377 2. Tezer H, Bedir Demirdag T. Novel coronavirus disease (COVID-19) in children. *Turk J Med Sci*
378 2020;50(SI-1):592-603.
- 379 3. Palacios Cruz M, Santos E, Velazquez Cervantes MA, Leon Juarez M. COVID-19, a worldwide public health
380 emergency. *Rev Clin Esp* 2020.

- 381 4. Xia S, Duan K, Zhang Y, et al. Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and
382 Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials. *Jama* 2020.
- 383 5. Folegatti PM, Ewer KJ, Aley PK, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against
384 SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. *Lancet*
385 2020;**396**(10249):467-478.
- 386 6. Wang F, Kream RM, Stefano GB. An Evidence Based Perspective on mRNA-SARS-CoV-2 Vaccine Development.
387 *Med Sci Monit* 2020;**26**:e924700.
- 388 7. Zhu FC, Guan XH, Li YH, et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored
389 COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind,
390 placebo-controlled, phase 2 trial. *Lancet* 2020;**396**(10249):479-488.
- 391 8. Zhu FC, Li YH, Guan XH, et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5
392 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial.
393 *Lancet* 2020;**395**(10240):1845-1854.
- 394 9. Rehman SU, Shafique L, Ihsan A, Liu Q. Evolutionary Trajectory for the Emergence of Novel Coronavirus
395 SARS-CoV-2. *Pathogens* 2020;**9**(3).
- 396 10. Lan J, Ge J, Yu J, et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2
397 receptor. *Nature* 2020;**581**(7807):215-220.
- 398 11. Azkur AK, Akdis M, Azkur D, et al. Immune response to SARS-CoV-2 and mechanisms of immunopathological
399 changes in COVID-19. *Allergy* 2020;**75**(7):1564-1581.
- 400 12. Arvin AM, Fink K, Schmid MA, et al. A perspective on potential antibody-dependent enhancement of
401 SARS-CoV-2. *Nature* 2020;**584**(7821):353-363.
- 402 13. Chen FF, Zhong M, Liu Y, et al. The characteristics and outcomes of 681 severe cases with COVID-19 in China.
403 *J Crit Care* 2020;**60**:32-37.
- 404 14. Ogawa J, Zhu W, Tonnu N, et al. The D614G mutation in the SARS-CoV2 Spike protein increases infectivity in
405 an ACE2 receptor dependent manner. *bioRxiv* 2020.
- 406 15. Sharma A. It is too soon to attribute ADE to COVID-19. *Microbes Infect* 2020;**22**(4-5):158.
- 407
- 408
- 409

410 **Figure legends**

411 **Fig. 1 Screening, randomization and inclusion in phase I clinical trial**

412

413 **Fig. 2 Variations in 48 cytokines in the serum of immunized individuals and the observation**
414 **of ADE.**

415 Levels of 48 cytokines were monitored in the serum of the subjects who received the vaccine
416 and placebo who were assigned to the 0, 14 schedule (black) or the 0, 28 schedule (blue).
417 Cytokines were Chemokines, interleukins (ILs), growth factors (GFs), colony stimulating
418 factors (CSFs), tumor necrosis factors (TNFs), interferon (IFNs). The levels of 48 cytokines
419 (pg/mL) in the serum of subjects before receiving vaccine and placebo are shown as gray
420 intervals between red spots in each figure. Control (Con, 0 EU), low dose (LD, 50 EU), middle
421 dose (MD, 100 EU) and high dose (HD, 150 EU).

422

423 **Fig. 3 The observation of ADE.**

424 a-c: Fold change in relative viral load of supernatant and cell lysate of mononuclear
425 cells/macrophages (a), DCs (b) and NK cells (c) from human PBMCs infected with SARS-CoV-2
426 at three MOI in the presence of a series of dilutions of vaccine immune serum (1:32, 1:64,
427 1:128, ... to 1:4096) quantified by real-time PCR. Viral load of cell lysate were normalized to
428 viral copies in cell lysate of Virus group at 12 hours, and viral load of supernatant were
429 normalized to viral copies in virus input at 0 hour. Vac-sera, vaccine immune antisera from
430 human; cov-sera, convalescent antisera from COVID-19 patients; ctrl-sera, control sera from
431 healthy human. Data are shown as the mean \pm SEM.

432 d: Fold change in relative viral load of supernatant and cell lysate of mononuclear
433 cells/macrophages, DCs and NK cells from human PBMCs infected with DENV-3 in the
434 presence of mAb against prM quantified by real-time PCR. Viral load of cell lysate were

435 normalized to viral copies in cell lysate of Virus group at 12 hours, and viral load of
436 supernatant were normalized to viral copies in virus input at 0 hour. Data are shown as the
437 mean \pm SEM.

438

439 **Fig. 4 Immune response induced in immunized human individuals with inactivated**
440 **SARS-Cov-2 vaccine in the 0, 14 and 0, 28 schedules.**

441 a. Neutralizing antibodies, ELISA antibodies (IgGs) against S protein, N protein and virion,
442 and the specific positive CTL responses against the S, N and virion antigens induced by
443 the inactivated vaccine in individuals assigned to the 0, 14 schedule after booster
444 immunization.

445 b. Neutralizing antibodies, ELISA antibodies (IgGs) against S protein, N protein and virion,
446 and the specific positive CTL responses against the S, N and virion antigens induced by
447 the inactivated vaccine in individuals assigned to the 0, 28 schedule after booster
448 immunization.

449 c. Neutralizing antibodies, ELISA antibodies (IgGs) against S protein, N protein and virion
450 induced by the inactivated vaccine in individuals assigned to the 0, 28 schedule on 90
451 days after booster immunization.

452 d. Neutralizing antibodies induced by the inactivated vaccine could identify pandemic
453 strains from all over the world.

454 Control (Con, 0 EU), low dose (LD, 50 EU), middle dose (MD, 100 EU) and high dose (HD, 150
455 EU). The antibody positive judgment threshold is marked with a dotted line in the figure. *,
456 $0.01 < p < 0.05$; **, $0.001 < p < 0.01$; ***, $p < 0.001$. The significant differences compared to the
457 control group (Con) are shown in black, those compared to the low-dose group in purple,
458 and those compared to the middle-dose group in red.

459

460 **Fig. 5 Genetic diversity of genes related to the immune response induced by the**
461 **inactivated SARS-Cov-2 vaccine.**

462 a. The fold changes in some of the differentially expressed genes involved in cytokine
463 production. Some important genes reported relating to COVID-19 were marked with the
464 pink rectangle.

465 b. The fold changes in some of the differentially expressed genes involved in T cell
466 activation.

467 c. The fold changes in some of the differentially expressed genes involved in B cell
468 activation.


469 d. The fold changes in some of the differentially expressed genes involved in DC cell
470 activation.


471 e. The fold changes in some of the differentially expressed genes involved in mononuclear
472 cell/macrophage activation.





473 f. The fold changes in some of the differentially expressed genes involved in NK cell
474 activation.





475 Each row represents one gene, and the samples are depicted in the columns. Red indicates
476 genes that were expressed at higher levels, and blue denotes genes that were expressed at
477 lower levels compared with the control group at the same time point. The color bars
478 represent the log₂ fold change.

479







(a) 0, 14 procedure**(b)** 0, 28 procedure




Table 1. Baseline characteristics of the study participants

Characteristic	Immunization Schedule: Day 0,14 (N=96)					Immunization Schedule: Day 0,28 (N=96)				
	Low dose group (n=24)	Medium dose group (n=24)	High dose group (n=24)	Placebo group (n=24)	Total (n=96)	Low dose group (n=24)	Medium dose group (n=24)	High dose group (n=24)	Placebo group (n=24)	Total (n=96)
Age										
18-29	9 (38%)	7 (29%)	11 (46%)	5 (21%)	32 (33%)	8 (33%)	4 (17%)	7 (29%)	5 (21%)	24 (25%)
30-39	4 (17%)	6 (25%)	7 (29%)	10 (42%)	27 (28%)	9 (38%)	7 (29%)	9 (38%)	10 (42%)	35 (36%)
40-49	7 (29%)	7 (29%)	3 (13%)	6 (25%)	23 (24%)	7 (29%)	11 (46%)	3 (13%)	7 (29%)	28 (29%)
50-59	4 (17%)	4 (17%)	3 (13%)	3 (13%)	14 (15%)	0	2 (8%)	5 (21%)	2 (8%)	9 (9%)
Mean(SD)	37.0±11.84	38.2±10.83	33.9±11.00	37.6±9.04	36.7±10.69	34.4±9.21	40.1±9.70	36.5±11.43	37.2±8.67	37.0±9.86
Sex										
Male	11 (46%)	8 (33%)	10 (42%)	14 (58%)	43 (45%)	9 (38%)	12 (50%)	10 (42%)	12 (50%)	43 (45%)
Female	13 (54%)	16 (67%)	14 (58%)	10 (42%)	53 (55%)	15 (63%)	12 (50%)	14 (58%)	12 (50%)	53 (55%)
BMI, kg/m²										
Mean(SD)	23.6±2.80	23.0±2.76	23.0±2.96	23.0±2.70	23.1±2.77	22.7±2.83	22.8±2.73	22.6±1.37	23.3±2.39	22.9±2.38
Ethnicity										
Han	24 (100%)	22 (92%)	22 (92%)	24 (100%)	92 (96%)	22 (92%)	24 (100%)	24 (100%)	24 (100%)	94 (98%)
Man	0	0	0	0	0	1 (4%)	0	0	0	1 (1%)
Hmong	0	1 (4%)	0	0	1 (1%)	0	0	0	0	0
Tujia	0	0	1 (4%)	0	1 (1%)	0	0	0	0	0
Tibetan	0	1 (4%)	1 (4%)	0	2 (2%)	1 (4%)	0	0	0	1 (1%)

BMI, body mass index; SD, standard deviation. 'n' used as denominator for calculation of percentage values.

Table 2. Adverse events within 28 days after vaccination in the safety population.

Adverse reactions	0,14 procedure				0,28 procedure			
	Low dose group (n=24)	Middle dose group (n=24)	High dose group (n=24)	Placebo group (n=24)	Low dose group (n=24)	Middle dose group(n=24)	High dose group(n=24)	Placebo group(n=24)
	<i>number of participants (%)</i>				<i>number of participants (%)</i>			
All adverse reactions within 0-7 days	8 (33.3)	4 (16.7)	4 (16.7)	3 (12.5)	5 (20.8)	7 (29.2)	9 (37.5)	4 (16.7)
Solicited injection site adverse reactions within 0-7 days								
Total	7 (29.2)	4 (16.7)	2 (8.3)	3 (12.5)	3 (12.5)	4 (16.7)	5 (20.8)	0 (0.0)
Pain	6 (25.0)	4 (16.7)	2 (8.3)	2 (8.3)	3 (12.5)	3 (12.5)	5 (20.8)	0 (0.0)
Itch	2 (8.3)	1 (4.2)	0 (0.0)	1 (4.2)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Redness	1 (4.2)	0 (0.0)	0 (0.0)	1 (4.2)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Swelling	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (4.2)	0 (0.0)	0 (0.0)
Solicited systemic adverse reactions within 0-7 days								
Total	3 (12.5)	1 (4.2)	1 (4.2)	0 (0.0)	2 (8.3)	4 (16.7)	4 (16.7)	3 (12.5)
Fatigue	2 (8.3)	1 (4.2)	0 (0.0)	0 (0.0)	2 (8.3)	3 (12.5)	3 (12.5)	2 (8.3)
Diarrhoea	0 (0.0)	1 (4.2)	1 (4.2)	0 (0.0)	0 (0.0)	0 (0.0)	1 (4.2)	0 (0.0)
Fever	1 (4.2)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (4.2)	0 (0.0)	0 (0.0)
Rash	1 (4.2)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (4.2)
Unsolicited adverse reactions within 0-7 days	2 (8.3)	0 (0.0)	2 (8.3)	0 (0.0)	0 (0.0)	2 (8.3)	3 (12.5)	1 (4.2)
Overall adverse reactions within 0-28 days	8 (33.3)	4 (16.7)	4 (16.7)	3 (12.5)	6 (25.0)	7 (29.2)	9 (37.5)	3 (12.5)

No severe (grade 3) adverse reaction and serious adverse events were observed within 28 days